Page last updated: 2024-10-22

amitriptyline and Dejerine-Roussy Syndrome

amitriptyline has been researched along with Dejerine-Roussy Syndrome in 2 studies

Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.
amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kluger, NJ1
Clifford, JS1
Cavanagh, RJ1
Griffith, WL1
Koppel, BS1

Other Studies

2 other studies available for amitriptyline and Dejerine-Roussy Syndrome

ArticleYear
A case of a chemically dependent patient with a thalamic pain syndrome treated with amitriptyline.
    Journal of addictive diseases, 1991, Volume: 10, Issue:3

    Topics: Alcoholism; Amitriptyline; Cerebral Infarction; Flurazepam; Follow-Up Studies; Humans; Male; Middle

1991
Amitriptyline in the treatment of thalamic pain.
    Southern medical journal, 1986, Volume: 79, Issue:6

    Topics: Adult; Aged; Amitriptyline; Female; Humans; Male; Pain, Intractable; Thalamic Diseases

1986